Salas-Huenuleo, E.; Hernández, A.; Lobos-González, L.; Polakovičová, I.; Morales-Zavala, F.; Araya, E.; Celis, F.; Romero, C.; Kogan, M.J.
Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells. Pharmaceutics 2022, 14, 958.
https://doi.org/10.3390/pharmaceutics14050958
AMA Style
Salas-Huenuleo E, Hernández A, Lobos-González L, Polakovičová I, Morales-Zavala F, Araya E, Celis F, Romero C, Kogan MJ.
Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells. Pharmaceutics. 2022; 14(5):958.
https://doi.org/10.3390/pharmaceutics14050958
Chicago/Turabian Style
Salas-Huenuleo, Edison, Andrea Hernández, Lorena Lobos-González, Iva Polakovičová, Francisco Morales-Zavala, Eyleen Araya, Freddy Celis, Carmen Romero, and Marcelo J. Kogan.
2022. "Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells" Pharmaceutics 14, no. 5: 958.
https://doi.org/10.3390/pharmaceutics14050958
APA Style
Salas-Huenuleo, E., Hernández, A., Lobos-González, L., Polakovičová, I., Morales-Zavala, F., Araya, E., Celis, F., Romero, C., & Kogan, M. J.
(2022). Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells. Pharmaceutics, 14(5), 958.
https://doi.org/10.3390/pharmaceutics14050958